Vaxcyte, Inc. (PCVX) stock
PCVXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$58.52−0.88 (-1.48%)
Close on Nov 18, 2026Market cap $8.71BP/E –Yield 0.00%
Vaxcyte free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Vaxcyte's free cash flow for the twelve months ending Jun 30, 2026 was -$894.14M. For fiscal 2025 it was -$669.29M. The highest annual figure on record is -$32.24M in fiscal 2018.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$669.29M | – |
| FY2024 | Dec 31, 2024 | -$475.05M | – |
| FY2023 | Dec 31, 2023 | -$312.85M | – |
| FY2022 | Dec 31, 2022 | -$176.44M | – |
| FY2021 | Dec 31, 2021 | -$127.95M | – |
| FY2020 | Dec 31, 2020 | -$47.78M | – |
| FY2019 | Dec 31, 2019 | -$48.34M | – |
| FY2018 | Dec 31, 2018 | -$32.24M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$236.79M | – |
| Q1 FY2026 | Mar 31, 2026 | -$282.73M | – |
| Q4 FY2025 | Dec 31, 2025 | -$227.49M | – |
| Q3 FY2025 | Sep 30, 2025 | -$147.13M | – |
| Q2 FY2025 | Jun 30, 2025 | -$122.98M | – |
| Q1 FY2025 | Mar 31, 2025 | -$171.70M | – |
| Q4 FY2024 | Dec 31, 2024 | -$115.42M | – |
| Q3 FY2024 | Sep 30, 2024 | -$65.66M | – |
| Q2 FY2024 | Jun 30, 2024 | -$129.18M | – |
| Q1 FY2024 | Mar 31, 2024 | -$164.80M | – |
| Q4 FY2023 | Dec 31, 2023 | -$134.06M | – |
| Q3 FY2023 | Sep 30, 2023 | -$64.89M | – |
| Q2 FY2023 | Jun 30, 2023 | -$60.60M | – |
| Q1 FY2023 | Mar 31, 2023 | -$53.30M | – |
| Q4 FY2022 | Dec 31, 2022 | -$66.36M | – |
| Q3 FY2022 | Sep 30, 2022 | -$39.39M | – |
| Q2 FY2022 | Jun 30, 2022 | -$40.06M | – |
| Q1 FY2022 | Mar 31, 2022 | -$30.62M | – |
| Q4 FY2021 | Dec 31, 2021 | -$52.48M | – |
| Q3 FY2021 | Sep 30, 2021 | -$30.13M | – |
| Q2 FY2021 | Jun 30, 2021 | -$30.89M | – |
| Q1 FY2021 | Mar 31, 2021 | -$14.45M | – |
| Q4 FY2020 | Dec 31, 2020 | -$11.49M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.08M | – |
| Q2 FY2020 | Jun 30, 2020 | -$9.23M | – |
| Q1 FY2020 | Mar 31, 2020 | -$13.98M | – |
| Q4 FY2019 | Dec 31, 2019 | -$15.36M | – |
| Q3 FY2019 | Sep 30, 2019 | -$9.52M | – |
See a number that looks wrong?